Intellia Therapeutics Inc. (NTLA) Director Muna Bhanji sold 1,867 shares of the company in a transaction on Thursday, July 6th. Director Munani Bhanj now holds 12.

Intellia Therapeutics Inc. (NTLA) Director Muna Bhanji sold 1,867 shares of the company in a transaction on Thursday, July 6th. Cyndeo Wealth Partners LLC acquired a new position in Intellya Therapeutic, Inc. in Stock. Intellia Therapeutics is anticipated to post earnings of ($4.05) per share for the year. This forecast comes amidst a consensus estimate of $5.33 per share. Director Muna Bhanji now holds 12,526 shares in the company valued at $492,271. Wall Street analysts think its a good time to buy Intellia Therapeutics stock. Out of 16 sell side analysts who give forecasts on NTLA, the consensus analyst rating is a Strong Buy. NTLA does not generate passive income. Cambridge, MA, is hiring associate director, clinical data management in cambridge, massachusetts, united states. Sandia Investment Management LP acquired a new position in shares of Intellia Therapeutics in the fourth quarter valued at approximately $35,000. CWM LLC boosted its holdings in shares by 2,072.7% in the first quarter. Raymond James & Associates owns 0.06% of Intellia Therapeutics worth $1,972,000 at the end of the most recent quarter. Director Muna Bhanji sold 1,867 shares of the businesss stock in a transaction on Thursday, July 6th.